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ABSTRACT
Objectives Diabetes is the leading cause of disability- 
adjusted life years in Mexico, and cost- effective care 
models are needed to address the epidemic. We sought 
to evaluate the cost and cost- effectiveness of a novel 
community- based model of diabetes care in rural Mexico, 
compared with usual care.
Design We performed time- driven activity- based costing 
to estimate annualised costs associated with typical 
diabetes care in Chiapas, Mexico, as well as a novel 
diabetes care model known as Compañeros En Salud 
Programa de Enfermedades Crónicas (CESPEC). We 
conducted Markov chain analysis to estimate the cost- 
effectiveness of CESPEC compared with usual care from 
a societal perspective. We used patient outcomes from 
CESPEC in 2016, as well as secondary data from existing 
literature.
Setting Rural primary care clinics in Chiapas, Mexico.
Participants Adults with diabetes.
Interventions CESPEC is a novel, comprehensive, 
diabetes care model that integrates community health 
workers, provider education, supply chain management 
and active case finding.
Outcome measure The primary outcome was the 
incremental cost- effectiveness of CESPEC compared with 
care as usual, per quality- adjusted life year (QALY) gained, 
expressed in 2016 US dollars.
Results The economic cost of the CESPEC diabetes 
model was US$144 per patient per year, compared with 
US$125 for diabetes care as usual. However, CESPEC 
care was associated with 0.13 additional years of health- 
adjusted life expectancy compared with usual care and 
0.02 additional years in the first 5 years of treatment. This 
translated to an incremental cost- effectiveness ratio (ICER) 
of US$2981 per QALY gained over a patient’s lifetime and 
an ICER of US$10 444 over the first 5 years. Findings were 
robust to multiple sensitivity analyses.
Conclusions CESPEC is a cost- effective, community- 
based model of diabetes care for patients in rural Mexico. 
Given the high prevalence and significant morbidity 
associated with diabetes in Mexico and other countries 
in Central America, this model should be considered for 
broader scale up and evaluation.
INTRODUCTION
Diabetes continues to rise as a leading cause of 
disability and mortality in the world and now 
ranks as the 12th leading cause of disability- 
adjusted life years (DALYs) worldwide.1 
There are an estimated 422 million patients 
in the world currently living with diabetes 
and 3.7 million diabetes- related deaths per 
year.2 The growing medical burden comes 
with concomitant economic costs. By some 
estimates, the yearly global cost of diabetes is 
US$1.31 trillion.3 In Mexico, where diabetes 
is the leading cause of DALYs and affects 
over 11.5 million adults,4–6 associated costs 
are rapidly increasing, currently representing 
15% of total health expenditure.6–8
Innovative, low cost models of diabetes care 
are needed to address the worsening health 
and economic challenges driven by diabetes. 
Strengths and limitations of this study
 ► This economic evaluation studied a novel, 
community- based diabetes care model (Compañeros 
En Salud Programa de Enfermedades Crónicas 
(CESPEC)) in a rural low- income and middle- income 
country, a setting in which few economic evalua-
tions exist, despite a high burden of diabetes in rural 
areas.
 ► We conducted detailed cost analysis using a rigor-
ous time- driven activity- based costing approach.
 ► Findings of cost- effectiveness of CESPEC were from 
a societal perspective and were robust to two differ-
ent time horizons and multiple sensitivity analyses.
 ► Limitations include: (1) using simplifying assump-
tions in the decision analysis model that likely gen-
erated conservative estimates of cost- effectiveness 
and (2) a limited geographic scope that tempers 
generalisability of our findings and warrants addi-
tional evaluation in other settings.
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Most existing cost- effectiveness studies in diabetes care are 
focused on narrow therapeutic interventions, as opposed 
to comprehensive models of care.9 This is despite the fact 
that international society guidelines emphasise multi-
component, interdisciplinary care models, with modest 
evidence available supporting cost- effectiveness.10–14 The 
evaluation of multicomponent diabetes care models in 
low- income and middle- income countries (LMICs) such 
as Mexico is limited, particularly evaluations that use 
economic analysis as a tool to assess the value of a large- 
scale investment to restructure care.
We assessed the cost and cost- effectiveness of a novel 
chronic disease management programme for diabetes 
care in rural Chiapas, Mexico, called the Compañeros 
En Salud Programa de Enfermedades Crónicas (CESPEC). 
We previously described the programme’s implemen-
tation and quantified its clinical effectiveness for 
improving diabetes and hypertension control, using 
thresholds set by the Secretariat of Health of Chiapas 
(SSCH in Spanish) as a haemoglobin A1c below 7% 
and a blood pressure <140/90 mm Hg.15 In this study, 
we performed an economic evaluation of CESPEC to: 
(1) estimate the annualised economic cost per patient 
with diabetes relative to the cost of care as usual and 
(2) estimate the incremental cost- effectiveness of 
CESPEC relative to care as usual, measured as cost 
per quality- adjusted life years (QALYs) gained. We 
hypothesised that CESPEC would be cost- effective 
when compared with a standard threshold of three 
times the national gross domestic product (GDP) per 
capita in Mexico16 and when compared with other 




Compañeros En Salud (CES) is the Mexico- based affiliate 
of Partners In Health, a non- governmental healthcare 
delivery organisation. Since 2011, CES has focused on 
health system strengthening and the provision of compre-
hensive primary care in rural Chiapas. Chiapas is one of 
the poorest states in Mexico and has the third lowest 
life expectancy in the country.19 20 Similar to the rest of 
Mexico, diabetes is the greatest cause of combined death 
and disability in the state.21
CES operates primary care clinics in 10 rural commu-
nities in the Sierra Madre region of the state, serving as 
the primary source of healthcare. CES runs in collabora-
tion with the SSCH, and the clinics are integrated into the 
broader public healthcare system. In other rural regions 
of Chiapas not supported by CES, the SSCH operates 
rural clinics directly. Both CES and non- CES communi-
ties share similar socioeconomic conditions, and addi-
tional details regarding the setting and socioeconomic 
comparisons are described elsewhere.15
Diabetes treatment models
We evaluated and compared two treatment models for 
the management of type 2 diabetes. First, we studied 
usual care at rural clinics run directly by the SSCH. Usual 
diabetes care at SSCH clinics consists of monthly, routine 
medical examinations with a general medical provider 
and nurse. Any medications prescribed during the visit 
are dispensed on- site through a pharmacy at no cost to 
the patient, subsidised by the SSCH. In this model, there 
are no additional resources or health education sessions 
outside of regular clinic visits.
The second model evaluated was CESPEC, a 
community- based non- communicable disease manage-
ment programme started in 2014 by CES. The programme 
consists of: (1) household engagement by community 
health workers (CHWs), (2) provider education and 
support, including evidenced- based algorithms to support 
decision making, (3) supplemental supply chain manage-
ment to procure medicines that previously suffered 
frequent stockouts and (4) active case finding in the 
community. For diabetes care, the CESPEC model involves 
monthly clinic visits with a physician who is completing a 
government- required social service year (pasante) before 
obtaining a full medical licence. Between clinic visits, 
additional patient teaching and follow- up is provided by 
CHWs depending on patient history of diabetes control. 
CHWs act as a liaison between the clinic and the patient, 
providing education, psychosocial support and medica-
tion adherence reinforcement. They are nominated by 
the community and compensated with food/consumable 
items. Communities also undergo regular screening with 
an active case- finding programme that occurs biannually. 
The design, implementation and clinical effectiveness 
of CESPEC has been previously published.15 Detailed 
process maps of the two comparative care delivery models 
are available in figure 1.
Cost analysis
We used time- driven activity- based costing (TDABC) to 
estimate the costs of both CESPEC and usual care.22–24 
TDABC involves determining the costs of the health-
care by directly observing patient flow through a health 
system, and assigning costs to each activity in a cycle of 
care based on activity duration and resources used, such 
as personnel, equipment and clinic space. We identified 
all activities related to diabetes care, as well as duration 
of each activity, through key informant interviews with 
medical personnel and direct observation of patients 
receiving care in August–December 2016. We adopted 
a societal perspective and included the opportunity cost 
of all involved individuals (including patients). Staff 
time was valued at full salary cost, including benefits. 
The cost of volunteered time at CES was estimated based 
on the salary of staff in similar, paid roles. We estimated 
the opportunity cost of patient time using local wages in 
Chiapas.19
Direct costs incurred by CESPEC were obtained from 
the organisational budget and price lists from actual 
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vendors. Costs for medications and labour for the SSCH 
clinics were obtained from multiple publicly available 
government pricing lists.25 26 We assumed 100% medi-
cation adherence with no stockouts. We estimated the 
cost of physical space based on area construction costs 
for equivalent square footage and assumed 20- year linear 
depreciation of physical space. For indirect costs, we 
calculated CES- related administration and overhead costs 
associated with operating the NGO. Central, state- level 
administrative costs were excluded from indirect cost 
calculations.
Our primary cost analysis outcome was the economic 
cost of diabetes care per patient per year in 2016 US 
dollars. We chose 2016 as the year of analysis since that 
is when direct field observations occurred and the year 
in which we collected CES budget information. We chose 
to report results in US dollars for general interpret-
ability and because many cost inputs were obtained in 
this currency. Costs that were obtained as Mexican pesos 
were converted to US dollars based on 2016 exchange 
rates.27 Any costs obtained from other years were infla-
tion adjusted to 2016 using the Mexican Consumer Price 
Index.28 29
Cost-effectiveness analysis
We estimated incremental cost- effectiveness ratios using a 
Markov modelling approach in TreeAge Pro Healthcare 
2020 (Williamstown, Massachusetts, USA). The decision 
analysis model accounted for diabetes control rates for 
CESPEC and usual care and their relationships to long- 
term health outcomes and diabetes- related complications 
(see online supplemental appendix figure 1 for a sche-
matic of the decision tree). The Markov cycle duration 
was 1 year, and we assumed a treatment effect of CESPEC 
for only 1 year. That is, the status of diabetes control could 
change from controlled to uncontrolled or vice versa 
in any subsequent Markov cycle. The model quantified 
probabilities and morbidity associated with microvascular 
complications (nephropathy, retinopathy and neurop-
athy) and macrovascular complications (stroke and 
Figure 1 Diabetes care process maps. (A) Diabetes care process maps for usual care. (B) Diabetes care process maps for 
CESPEC. CESPEC, Compañeros En Salud Programa de Enfermedades Crónicas; CHW, community health worker.
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myocardial infarction), making two simplifying assump-
tions. First, we conservatively assumed microvascular 
complications were permanent and mutually exclusive. 
Second, we also assumed macrovascular complications 
were transient events that could recur and did not result 
in long- term sequelae. In our base case scenario, we 
adopted a lifetime analytical horizon. We also modelled an 
additional time horizon of 5 years to evaluate short- term 
incremental cost- effectiveness of CESPEC relative to care 
as usual. The patient cohort entered the Markov model 
at age 40 years, given the rapid rise in diabetes incidence 
that occurs around age 40 years in Chiapas, as reported 
in Global Burden of Disease data.30 We employed a half- 
cycle correction in Markov models and incorporated a 
global discount rate of 3% for both cost and QALYs.16 17
For cost estimates in the models, we used the 
parameters identified from our cost analysis as inputs 
for the annual cost of diabetes care under the usual 
care and CESPEC models. Other model parameters 
were drawn from existing literature, considering the 
recency, quality and appropriateness of studies. For 
the costs of complications, we used national estimates 
from Mexico as reported by Fundación Mexicana para 
la Salud.31 Other studies evaluating costs in Mexico 
either do not provide separate estimates of individual 
complications or provide aggregate population costs 
instead of a per patient annual cost.32 Transition prob-
ability inputs were obtained from the existing litera-
ture. Where possible, we selected high- quality studies 
from Mexican populations. Otherwise, we selected 
the best available studies with detailed assessment of 
complications based on disease control. We derived 
health- adjusted quality of life inputs for disease states 
using the inverse of disability weights from the 2016 
Global Burden of Disease study.33 34 A detailed discus-
sion of study selection, methods and a table of model 
parameters is available in the online supplemental 
appendix.
Our primary outcome for cost- effectiveness analyses 
was the incremental cost- effectiveness ratio (ICER) per 
QALY gained for the base case scenario. We chose QALYs 
instead of DALYs as our primary outcome as an estab-
lished and accepted measure used by policymakers to 
assess intervention cost- effectiveness. We considered an 
ICER less than three times 2016 GDP per capita in Mexico 
(US$26 219.28)35 to be cost- effective, based on estab-
lished guidelines.16 ICERs less than one time the GDP per 
capita (US$8739.76) were considered very cost- effective. 
We acknowledge that a fixed GDP- based threshold fails 
to incorporate local context and competing health 
policy priorities in determining cost- effectiveness,18 
and we therefore also qualitatively evaluated the ICERs 
compared with ICERS of similar interventions, reflected 
in the discussion section.
We performed sensitivity analyses to assess the effect 
of input parameter uncertainty on our cost- effectiveness 
estimates. First, we performed one- way determin-
istic sensitivity analyses by varying individual input 
parameters. Specifically, we varied programme cost esti-
mates and diabetes control probability from 80% to 120% 
of point estimate values for both CESPEC and usual care. 
We also varied the costs of complications from 80% to 
120%. Second, we performed a scenario- based determin-
istic sensitivity analysis, in which we assumed all medical 
providers in CESPEC were general medical providers 
instead of pasantes, as pasantes are paid significantly less. 
Third, we performed probabilistic sensitivity analysis by 
varying all model parameters simultaneously by sampling 
from their respective distributions (online supplemental 
appendix table 1) following a Monte Carlo approach 
with 10 000 simulations. We assessed that 10 000 simula-
tions was sufficient to produce stable results by testing for 
model convergence.36
Patient and public involvement
There was no patient or public involvement in the design, 
conduct, reporting or dissemination of this study.
RESULTS
Cost analysis
The cost of usual care at SSCH clinics in 2016 was US$125 
per patient per year. This estimate was based on US$99 in 
visit costs and $26 in medication costs. The per visit cost 
was US$8.25, of which personnel accounted for 89% of 
per visit costs, followed by resources at 7% and physical 
space at 4% of per visit cost (table 1).
CESPEC services cost US$144 per patient per year. Visits 
only accounted for 32% of total CESPEC costs, compared 
with 79% in usual care, because CESPEC relies primarily 
on pasantes for service delivery. CESPEC also incurred 
an additional US$53.26 per patient per year of indirect 
costs, including general administrative costs (US$12.31), 
coordinating CHWs (US$34.24) and active case finding 
(US$6.71). The per visit cost was US$4.02, again primarily 
driven by personnel that accounted for 90% of the per visit 
cost, followed by resources at 16% and physical space at 4% 
of per visit cost. The opportunity cost for a patient to partic-
ipate in a visit was estimated at US$0.96 in lost wages.
Cost-effectiveness analysis
Based on the health states and transition probabilities 
associated with CESPEC and care as usual, estimated 
gains in health- adjusted life expectancy for CESPEC 
recipients was 15.40, compared with 15.26 among indi-
viduals receiving care as usual. Limited to the first 5 years 
of treatment, gains in health- adjusted years were 4.15 for 
CESPEC recipients and 4.13 among recipients of care as 
usual (table 2).
Under the base case scenario of a lifetime time 
horizon, we estimated an ICER for CESPEC of 
US$2981 per QALY gained, which is considered very 
cost- effective insofar as this is below Mexico’s GDP per 
capita (US$8739.76). Under a 5- year time horizon, the 
ICER for CESPEC remained cost- effective at US$10 444 
per QALY gained.
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Sensitivity analysis
One- way sensitivity analyses demonstrated that CESPEC 
remained very cost- effective despite varying multiple 
parameters from 80% to 120% of their point estimates 
(figure 2). The ICER for CESPEC was most sensitive to 
changes in the estimated programme cost of CESPEC, 
which varied from CESPEC dominating usual care to 
an ICER of US$6346 per QALY gained (online supple-
mental appendix table 2). In the scenario under which 
we assumed that all providers in CESPEC were higher 
paid general medical providers (not pasantes), we 
input a CESPEC programme cost of $232 per patient 
per year. We calculated an ICER of US$13 509 per 
QALY gained in this scenario, again considered cost- 
effective at the threshold of three times national GPD 
per capita. In the probabilistic sensitivity analysis, 
we calculated a mean ICER of US$3770.33 (table 2). 
CESPEC was cost- effective in 83% of scenarios at 
the willingness- to- pay of three times GDP per capita 
(figure 3). We confirmed that our model converged 
and produced stable probabilistic sensitivity analysis 
results after 10 000 simulations, as the mean incre-
mental net monetary benefit 95% CI did not include 
zero (table 2).36
DISCUSSION
In this economic evaluation of two diabetes care models in 
rural Chiapas, Mexico, we found that the novel CESPEC 
model of care provides high- value, cost- effective diabetes 
care relative to care as usual. We estimated that CESPEC 
costs US$2940 per QALY gained when viewed over an 
individual’s lifespan. The estimated ICER is similar to 
other ICERs in high- income countries for diabetes educa-
tion and multicomponent interventions that have a 
median cost in the range of US$2315–US$5047 per QALY 
gained.14 Locally, estimates from Mexico suggest that 
intensively controlling diabetes would cost US$12,500–
US$16 900 per QALY gained.37 CESPEC compares favour-
ably with these existing estimates from the literature. 
Using GDP- based ICER thresholds,16 CESPEC is consid-
ered very cost- effective and remains cost- effective even 
when limited to the first 5 years of treatment. To our 
knowledge, this is the first study measuring the economic 
value of a rural comprehensive diabetes management 
programme in an LMIC.38
Our cost analysis found that CESPEC is more expen-
sive compared with usual care within SSCH clinic. This 
is primarily due to indirect costs associated with CESPEC 
care delivery. CESPEC requires additional personnel and 
resources for all four components of the programme, 
including provider education, supply chain management, 
CHWs and active case finding. While these four compo-
nents generate additional costs, they do not exist in usual 
care and are the high- value interventions that underly the 
clinical effectiveness of CESPEC in improving diabetes 
control. We posit that the CHW model and supply chain 
management components are particularly important, 
as previous research in rural Chiapas indicates a lack of 
trust in centralised health systems and supply shortages in 
medicines that undermine patient engagement.39 Further 
work is needed to study the value of each CESPEC compo-
nent individually and to determine whether they are addi-
tive or synergistic when combined.
The CESPEC care delivery model remained cost- 
effective in the context of multiple sensitivity analyses. 
This is particularly important because clinics using the 
CESPEC model are staffed exclusively by pasante physi-
cians that are lower cost than typical licenced medical 
providers. By contrast, SSCH clinics that deliver stan-
dard care are usually staffed by non- pasantes. Our find-
ings indicate that, even if CESPEC were staffed entirely 
by non- pasantes, it would remain cost- effective. This lends 
greater external validity to our cost- effectiveness findings 
as a potential model for scale up in other rural regions of 
Mexico.
Our findings have significant policy implications. In 
2016, the Mexican government declared diabetes as a 







Per visit per patient $8.25 $4.02
  Personnel $7.32 $3.24
   Patient $2.23 $0.96
   Medical provider $3.75 $1.04
   Nurse $1.13 N/A*
   Pharmacy technician $0.21 N/A*
   Clinical supervisor N/A* $1.24
  Resources $0.63 $0.63
   Lab equipment $0.00† $0.00†
   Lab reagents/test strips $0.63 $0.63
  Clinic space $0.30 $0.15
   Waiting room $0.22 $0.04
   Clinic room $0.06 $0.09
   Pharmacy area $0.02 $0.02
   Nurse area $0.00† N/A*
Per patient per year
  Visits $99.04 $45.74
  Medications $25.79 $44.69
  Indirect costs N/A‡ $53.26
Total cost per patient per year $124.83 $143.69
*Cost element was not a part of this particular care model.
†The per visit per patient cost of this cost element was estimated 
to be less than 1 US cent.
‡Centralised state- level administrative costs were assumed to be 
the same across both CESPEC and usual care and excluded from 
the analysis.
CESPEC, Compañeros En Salud Programa de Enfermedades 
Crónicas.
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national public health emergency, devoting political and 
financial resources towards the prevention, identification 
and treatment of the disease.40 Many public and private 
programmes have been launched in an effort to tackle 
the diabetes epidemic in Mexico,41 but rigorous evidence 
of programme effectiveness or economic value is limited. 
Furthermore, none of these existing programmes is 
focused on rural populations, despite a high prevalence 
of diabetes in both urban and rural Mexico.42 Delivering 
high- quality diabetes care to rural populations is crit-
ical as these groups face additional barriers in access to 
care43 and suffer more catastrophic health expenditures 
compared with urban populations.44 CESPEC offers 
a clinically effective and high- value model of diabetes 
care for rural settings that can be achieved with targeted 
investments. All CES clinics operate within the existing 
public health infrastructure and do not operate as a 
parallel system. As such, CESPEC as a whole, or its key 
components, could supplement the existing public 
health system by improving health services delivered to 
historically marginalised communities without needing 
significant structural change.39 In addition, our model-
ling of different time horizons found that CESPEC is cost- 
effective even on a short time horizon, which highlights 

















Base case (lifetime time horizon)
  Usual care $12 044.99 15.26 Ref Ref Ref Ref
  CESPEC $12 440.76 15.40 $395.77 0.13 $2981.49 $3084.65
5- year time horizon
  Usual care $1413.31 4.13 Ref Ref Ref Ref
  CESPEC $1575.39 4.15 $162.08 0.02 $10 444.29 $3477.78
Probabilistic sensitivity analysis†
  Usual care $11 801.34 15.35 Ref Ref Ref Ref
  CESPEC $12 274.86 15.48 $473.52 0.13 $3770.33‡ $2819.38
(95% CI $2758 to $2881)
*INMB calculated using a willingness- to- pay threshold of US$26 219.28 (three times the gross domestic product per capita in Mexico).
†Outcomes reported are means of 10 000 Monte Carlo simulations.
‡95% CI not calculated for the ICER due to the challenge in calculating variance of a ratio of two variables. Instead, cost- effectiveness 
acceptability curves are presented elsewhere per CHEERS guidelines.47
CESPEC, Compañeros En Salud Programa de Enfermedades Crónicas; ICER, incremental cost- effectiveness ratio; INMB, incremental net 
monetary benefit; QALY, quality- adjusted life year.
Figure 2 One- way deterministic sensitivity analysis results. CKD, chronic kidney disease; CESPEC,Compañeros En Salud 
Programa de Enfermedades Crónicas; ICER, incrementalcost- effectiveness ratio; QALY, quality- adjusted life year.
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the potential for this model to make an immediate 
impact in efforts to improve population health. Further 
study is needed to test the generalisability and scalability 
of CESPEC in other rural regions, especially given the 
heterogeneous populations throughout rural Mexico.45 
Efforts to scale CESPEC should also consider how the 
model would interface differently with each of Mexico’s 
separately administered and financed public healthcare 
systems.
This study has several limitations. First, we used 
population- level data inputs for the Markov model. While 
valuable for policy decisions, a patient- level microsimula-
tion approach may provide more precise estimates. This 
technique requires more granular data than were avail-
able for our study. Second, we made simplifying assump-
tions in our decision tree for the purposes of constructing 
the model, such as limiting the number of microvascular 
complications a patient could develop. However, we know 
from clinical experience that patients can suffer multiple 
complications from diabetes simultaneously.46 Therefore, 
we expect that the ICER estimates in this study are likely 
conservative and may represent an upper bound. Third, 
one of the key parameters that differed between CESPEC 
and usual care was the probability of diabetes control. We 
used 1 year diabetes control figures based on previously 
identified estimates,15 but diabetes control figures greater 
than 1 year would provide more confidence in our esti-
mates. This limitation was mitigated using sensitivity anal-
yses to vary estimates of assumed clinical effectiveness. 
Fourth, we ascertained the duration of each activity for 
TDABC at 4 of 10 CES communities but only one usual 
care SSCH clinic. We accounted for this uncertainty with 
multiple sensitivity analyses. Fifth, we made the simpli-
fying assumption that utility weights are equivalent to the 
inverse of disability weights due to limitations in utility 
weight data availability in LMICs. Based on past analyses 
examining both QALYs and DALYs, the resulting esti-
mates are unlikely to meaningfully change the overall 
interpretation.34 Sixth, many of our transition probabil-
ities were derived from studies in high- income countries 
since estimates were not available from Mexican settings. 
These transition probabilities may differ from those of 
Mexican patients and could influence our results. Despite 
these limitations, our study has significant strengths, 
including a societal cost perspective taking into account 
opportunity cost of patients, a rigorous TDABC costing 
approach, a Markovian framework for cost- effectiveness 
analysis with multiple time horizons and three sensitivity 
analyses to strengthen confidence in our estimates.
CONCLUSION
CESPEC is a novel and high- value diabetes care model 
in rural Mexico that focuses on community engage-
ment, continuing medical education to health workers 
and community members, supply chain management 
and active case finding. The programme costs $144 per 
patient per year and is highly cost- effective at US$2981 
per QALY gained. Further study is needed to evaluate 
whether CESPEC can be successfully scaled and evaluated 
in other rural regions of Mexico.
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• Transition probabilities: To estimate the probability of achieving diabetes control with Compañeros En 
Salud Programa de Enfermedades Crónicas (CESPEC) compared to usual care, we utilized 
probabilities from our previous study that compared the two care models using a difference-in-
differences approach.1 For other transition probabilities, we sought high quality studies from Mexico 
that would provide the rate or probability of developing diabetes complications, stratified by whether 
diabetes was controlled or uncontrolled. This level of detail was available in a Mexican setting for 
mortality,2 but was not available for other diabetes complications. To estimate the probability of 
developing these other diabetes complications, we selected three landmark diabetes trials conducted in 
Western nations.3–5 The three studies we selected also carry the three highest study weights in a 
Cochrane review.6 To assess the risk of developing a macrovascular diabetes complications after 
already having a microvascular complication, we identified a study based on the ADVANCE trial to 
derive transition probabilities.7 
• Costs: The estimation of the cost of the CESPEC intervention and usual care are detailed in the main 
manuscript. The cost of diabetes complications were drawn from a report by Barraza-Lloréns et al. that 
is based in the Mexican health care setting. This is the only study we identified that estimates a per 
person or per event cost for diabetes complications in Mexico. Other estimates of diabetes costs in 
Mexico reported in the literature are population-level studies that only report aggregated total costs for 
the entire Mexican health care system.8 
• Health states: To calculate quality-adjusted life years (QALYs) reported in Appendix Table 1, we used 
disability weights from the Global Burden of Disease study given their comprehensiveness and 
established use in global health settings.9 Full details of the derivation of QALYs is reported below in 
the “Primary outcome” section. 
 
Transition probability calculation 
For multiple model parameters, the original studies reported outcomes as rates (outcome events per unit time). 
For a given rate (r) and time period (t), a transition probability (p) was calculated using the following equation:10 
 
𝑝 = 1 − 𝑒!"# 
 
For transition probability model parameters derived from multiple data sources (nephropathy, neuropathy, 
retinopathy, stroke and myocardial infarction), we then calculated a weighted average transition probability 
using the meta-analysis weights reported in a Cochrane analysis.6 
 
Sensitivity analysis: uncertainty of model parameters 
To characterize uncertainty in the probabilistic sensitivity analysis, we used beta distributions for binary 
outcomes and gamma distributions for costs. Distributions were fit for probabilistic sensitivity analysis by using 
the method of moments approach.10 Using this approach, we used the point estimate mean and standard 
errors reported by the selected studies to calculate distribution parameters. In one data source (Barraza-
Lloréns et al.), no standard errors were reported for the cost point estimates. This report calculated per person 
costs utilizing multiple studies. Where possible, we reviewed the original, referenced studies to derive the 
standard errors. If not available, we used existing standard errors from other estimates in the report to 
calculate new standard errors that were proportional to the magnitude of the cost estimate. 
 
Primary outcome 
We selected QALYs as our primary outcome for the cost-effectiveness analysis, given our aim to measure the 
effectiveness of an intervention, as opposed to an assessment of disease burden (for which disability-adjusted 
life years may be preferred).11 However, there is a lack of published utility weights for multiple diabetes health 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
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states and from low- and middle-income countries that we needed for our decision analysis model. Most utility 
weights that exist for diabetes are derived in high-income countries.12 Instead of using available utility-weights 
from high-income countries, we took the approach of utilizing disability weights under the assumption that Q=1-
D, where Q is the utility weight and D is the disability weight. Though there are differences in how utility and 
disability weights are derived, this approach provided several advantages. First, it allowed us to calculate 
QALYs for the entire model using a uniform set of disability weights from the Global Burden of Disease study 
that were derived using the same methodology.9 Second, these disability weights were developed for use in 
global health settings and low- and middle-income countries. Our approach has been evaluated empirically,13 
and has been utilized in other cost-effectiveness analyses.14 Furthermore, studies evaluating the use of both 
QALYs and DALYs to determine cost-effectiveness usually lead to similar interpretations and conclusions.15 
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Per patient per year    




Barraza-Lloréns et al (2015)16 
Nephropathy (CKD I-IV) $346.18 
(30.67) 
γ 
Barraza-Lloréns et al (2015)16 
Nephropathy (CKD V) $19,445.84 
(1722.53) 
γ 
Barraza-Lloréns et al (2015)16 




Barraza-Lloréns et al (2015)16 
Myocardial infarction $6,269.76 
(681.44) 
γ 
Barraza-Lloréns et al (2015)16 




Per patient per year    
CESPEC $143.69 (2.29) γ Table 1 
Usual care $124.83 (5.98) γ Table 1 
Transition probabilities 




Diabetes control a    
Controlled in CESPEC 0.526 (0.018) ß Duan et al (2018)1 
Controlled in usual care 0.277 (0.002) ß Duan et al (2018)1 
Neuropathy    
Diabetes controlled 
0.081 (0.028) b ß 
UKPDS (1998),3 ACCORD (2008),4 ADVANCE 
(2008)5  
Diabetes uncontrolled 
0.083 (0.028) b ß 
UKPDS (1998),3 ACCORD (2008),4 ADVANCE 
(2008)5 
Retinopathy    
Diabetes controlled 
0.014 (0.002) b ß 
UKPDS (1998),3 ACCORD (2008),4 ADVANCE 
(2008)5 
Diabetes uncontrolled 
0.015 (0.002) b ß 
UKPDS (1998),3 ACCORD (2008),4 ADVANCE 
(2008)5 
Nephropathy (CKD I-IV)    
Diabetes controlled 
0.055 (0.036) b ß 
UKPDS (1998),3 ACCORD (2008),4 ADVANCE 
(2008)5 
Diabetes uncontrolled 
0.057 (0.036) b ß 
UKPDS (1998),3 ACCORD (2008),4 ADVANCE 
(2008)5 
Nephropathy (CKD V)    
Diabetes controlled 
0.004 (0.001) b ß 
UKPDS (1998),3 ACCORD (2008),4 ADVANCE 
(2008)5 
Diabetes uncontrolled 
0.005 (0.002) b ß 
UKPDS (1998),3 ACCORD (2008),4 ADVANCE 
(2008)5 
Stroke    
Diabetes controlled 
0.006 (0.001) b ß 
UKPDS (1998),3 ACCORD (2008),4 ADVANCE 
(2008)5 
Diabetes uncontrolled 
0.006 (0.001) b ß 




0.009 (0.003) ß 
Mohammedi et al (2017)7 
Myocardial infarction    
Diabetes controlled 
0.010 (0.003) b ß 
UKPDS (1998),3 ACCORD (2008),4 ADVANCE 
(2008)5 
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Diabetes uncontrolled 
0.013 (0.004) b ß 




0.008 (0.003) ß 
Mohammedi et al (2017)7 
All-cause death    
Diabetes controlled 0.010 (0.001) ß Herrington et al (2018)2 
Diabetes uncontrolled 0.016 (0.001) ß Herrington et al (2018)2 
Existing microvascular 
disease 
0.026 (0.006) ß 
Mohammedi et al (2017)7 
Quality of life (QALYs)    
Diabetes (uncomplicated) 0.951 (0.010) ß IHME (2017)9 
Neuropathy 0.867 (0.025) ß IHME (2017)9 
Retinopathy 0.866 (0.025) c ß IHME (2017)9 
Nephropathy (CKD I-IV) 0.922 (0.015) c ß IHME (2017)9 
Nephropathy (CKD V) 0.414 (0.084) c ß IHME (2017)9 
Stroke 0.691 (0.049) c ß IHME (2017)9 
Myocardial infarction 0.900 (0.019) c ß IHME (2017)9 
Discount rate 0.03 N/A N/A 
SE=standard error; CKD=chronic kidney disease; CESPEC=Compañeros En Salud Programa de Enfermedades 
Crónicas; QALY=quality-adjusted life year; UKPDS=United Kingdom Prospective Diabetes Study; ACCORD=Action to 
Control Cardiovascular Risk in Diabetes; ADVANCE=Action in Diabetes and Vascular Disease; IHME=Institute of Health 
Metrics and Evaluation 
a Diabetes control is defined by the Secretariat of Health of Chiapas as a hemoglobin A1c below 7% or (if not available) a 
fasting blood glucose level below 7.16 mmol/l (130 mg/dl) 
b Weighted average based on meta-analysis weights in Hemmingsen et al (2013)6  
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ICER Low ICER High 
ICER 
Spread 
Cost of CESPEC $114.95 $143.69 $172.43 Dominated $6,407.25 $6,851.53 
Cost of usual care $99.86 $124.83 $149.80 $253.11 $5,709.86 $5,456.75 
Probability of diabetes control 
in CESPEC 
0.42 0.53 0.63 $2,096.32 $4,683.51 $2,587.19 
Probability of diabetes control 
in usual care 
0.22 0.28 0.33 $2,550.64 $3,524.32 $973.68 
Cost of nephropathy (CKD V) $15,556.67 $19,445.84 $23,335.01 $2,845.18 $3,117.80 $272.63 
Cost of stroke $10,662.56 $13,328.20 $15,993.84 $2,953.02 $3,009.96 $56.93 
Cost of nephropathy (CKD I-
IV) 
$276.94 $346.18 $415.42 $2,963.47 $2,999.51 $36.04 
Cost of myocardial infarction $5,015.81 $6,269.76 $7,523.71 $2,968.56 $2,994.42 $25.86 
Cost of neuropathy $55.22 $69.02 $82.82 $2,976.57 $2,986.40 $9.83 
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